Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy

Saved in:
Bibliographic Details
Published inClinical pharmacology and therapeutics Vol. 90; no. 2; p. 328
Main Authors Scott, S A, Sangkuhl, K, Gardner, E E, Stein, C M, Hulot, J-S, Johnson, J A, Roden, D M, Klein, T E, Shuldiner, A R
Format Journal Article
LanguageEnglish
Published United States 01.08.2011
Subjects
Acute Coronary Syndrome - therapy
Alleles
Angioplasty, Balloon, Coronary - methods
Aryl Hydrocarbon Hydroxylases - genetics
Aryl Hydrocarbon Hydroxylases - metabolism
Clopidogrel
Cytochrome P-450 CYP2C19
Genotype
Humans
Pharmacogenetics - methods
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - metabolism
Platelet Aggregation Inhibitors - therapeutic use
Ticlopidine - adverse effects
Ticlopidine - analogs & derivatives
Ticlopidine - metabolism
Ticlopidine - therapeutic use
Online AccessGet more information

Cover

More Information
ISSN:1532-6535
DOI:10.1038/clpt.2011.132